Comparative analysis of generic drug versions and different prices of Mobocertinib

Mobocertinib is an oral targeted drug mainly used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. The drug was developed by Japan's Takeda Pharmaceutical and has been approved for marketing in China. However, because it has not yet been included in the medical insurance catalog, patients still face a large financial burden when purchasing it domestically. Although domestic approval provides patients with more treatment options, many patients will still consider overseas channels or generic alternatives due to drug accessibility and price issues.

In terms of market supply, the original drug of mobosetinib is mainly sourced from the Hong Kong market and Japanese Takeda original research channels, and the price is generally higher. The price of a box of original medicine is usually around 7,000 to 8,000 yuan, and even for the Hong Kong version, the price has not dropped significantly. For some patients, such costs mean greater financial pressure for long-term treatment, so the market demand for more cost-effective generic drugs has increased significantly.

In the generic drug market, the Lao version of the generic version of moboxetinib has attracted attention. The price of this version is about 3,000 yuan, which is only half or even lower than the price of the original drug. According to public information, its drug ingredients are consistent with the original drug, and its efficacy and safety are basically the same. This makes the Lao version of generic drugs a realistic choice for many patients. At the same time, due to the price advantage of generic drugs, they have gradually become the mainstream choice among some patient groups, especially in the case of long-term medication, where the cost gap is particularly significant.

Overall, the market structure of mobosertinib is gradually showing a dual-track model of "original drugs+ generic drugs". For patients with better financial conditions, they can choose Takeda’s original drug or the Hong Kong version to ensure the stability of genuine channels and clinical use; while for patients with greater economic pressure, the Lao version of generic drugs is a more cost-effective alternative. With the dynamic adjustment of domestic medical policies and medical insurance catalogs, if moboxetinib can be included in medical insurance in the future, its accessibility will be significantly improved, and more patients will benefit from it.

Reference link:https://www.drugs.com